Stock Price Quote

HESTER BIOSCIENCES LTD.

NSE : HESTERBIOBSE : 524669ISIN CODE : INE782E01017Industry : Pharmaceuticals & DrugsHouse : Private
BSE1760.30-10.2 (-0.58 %)
PREV CLOSE ( ) 1770.50
OPEN PRICE ( ) 1787.60
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 219
TODAY'S LOW / HIGH ( )1745.25 1808.45
52 WK LOW / HIGH ( )1246.75 3375.45
NSE1760.00-25.5 (-1.43 %)
PREV CLOSE( ) 1785.50
OPEN PRICE ( ) 1789.60
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 5481
TODAY'S LOW / HIGH( ) 1744.60 1805.90
52 WK LOW / HIGH ( )1242.95 3379
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 1987
Management Info
Bhupendra V Gandhi - Chairman Rajiv Gandhi - Managing Director
Registered Office

Address Meda Adraj , Kadi, , ,
Mehsana,
Gujarat-384441

Phone 079 – 26445106

Email mail@hester.in

Website www.hester.in

Registrars Details
MUFG Intime India Pvt Ltd.
506-508, 5th Floor, Amaranth Business Complex - I (ABC - I),Beside Gala Business Center, St. Xaviers Corner, Off C.G. Road,Navrangpura,Ahmedabad
Listing : BSE, NSE

NEWS

10May Hester Biosciences informs about news
In compliance with Regulation 30 of the SEBI (Listing Obligations and Di..
09May Hester Biosciences informs about outco
Hester Biosciences has informed that with reference to the letter dated..
09May Hester Biosciences informs about outco
Hester Biosciences has informed that Board of Directors, in their Meetin..
09May Hester Biosciences informs about outco
Hester Biosciences has informed that Board of Directors, in their Meetin..
02May Hester Biosciences informs about board
Hester Biosciences has informed that, as per Regulation 29 of the SEBI (..

Financials

in Millions
QTR Mar 25 ANNUAL 25
Net Profit96.3499999999999318.42
Gross Profit 114.83 417.6
Operating Profit 147.6557.08
Net Sales 766.722864.66

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Abbott India (BSE)
peergroup  31422.10 (2.05%)
M.Cap ( in Cr)66769.77
Glaxosmithkline Phar (BSE)
peergroup  2984.45 (7.07%)
M.Cap ( in Cr)50558.38
Caplin Point Lab (BSE)
peergroup  2250.95 (5.75%)
M.Cap ( in Cr)17109.85
Alkem Laboratories (BSE)
peergroup  5377.15 (2.21%)
M.Cap ( in Cr)64291.89
Divi's Lab (BSE)
peergroup  6550.90 (1.55%)
M.Cap ( in Cr)173905.81

Shareholding Pattern

PROMOTERS 53.73%
NON-INSTITUTION 45.39%
MUTUAL FUNDS/UTI 0%
FI/BANKS/INSURANCE 0%
GOVERNMENT 0%
FII 0%

About Hester Biosciences Ltd.

Hester Biosciences Ltd. was incorporated in the year 1987. Its today's share price is 1760.3. Its current market capitalisation stands at Rs 1497.46 Cr. In the latest quarter, company has reported Gross Sales of Rs. 2853.88 Cr and Total Income of Rs.2899.07 Cr. The company's management includes Bhupendra V Gandhi, Nina Gandhi, Ravin Gandhi, Sanjiv Gandhi, Priya Gandhi, Vinod Mali, Jatin Trivedi, Anil Jain, Ameet Desai, Ashok Bhadakal, Sandhya Patel, Rajiv Gandhi.

It is listed on the BSE with a BSE Code of 524669 , NSE with an NSE Symbol of HESTERBIO and ISIN of INE782E01017. It's Registered office is at Meda Adraj , Kadi, , Mehsana-384441, Gujarat. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Apaji Amin & Co LLP, Chandulal M Shah & Co, Shah Karia & Associates, Shah Narielwala & Co

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.